---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-005614"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:56:48.487754+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seres reports preliminary Q4 VOWST net sales of $10.4M; FDA Fast Track for SER-155

## Summary
- VOWST Q4 2023 net sales approx $10.4M (unaudited); total 2023 net sales since June launch approx $19.6M.
- 2,833 patient enrollment forms received and 2,015 new patient starts since launch through year-end 2023.
- SER-155 received FDA Fast Track Designation; Phase 1b Cohort 2 data readout expected in Q3 2024.
- Preliminary cash, cash equivalents, and investments of approx $128M as of Dec 31, 2023.
- Company expects cash plus expected $45M Tranche B from Oaktree to support operations into Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-005614
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/0001193125-24-005614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/d129973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-005614
- JSON: https://secwatch.observer/filing/0001193125-24-005614.json
- Plain text: https://secwatch.observer/filing/0001193125-24-005614.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue net sales of VOWST of approximately $10.4 million (unaudited).
  - Period: the fourth quarter of 2023
  - Revenue: net sales of VOWST of approximately $10.4 million (unaudited)
  - Result: preliminary results
  source text: On January 9, 2024, Seres Therapeutics, Inc. (the “Company”) issued a press release in which the Company announced, among other things, that based on preliminary financial results, the Company had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 2023, and preliminary cash, cash equivalents and investments of approximately $128 million (unaudited) as of December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/0001193125-24-005614-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.